Mark D. Hafermann

Adjuvant Radiotherapy Following Radical Prostatectomy: Results and Complications

Between 1954 and 1978, 148 patients underwent radical perineal prostatectomy for adenocarcinoma clinically confined to the prostate gland. This report is based on 45 of these patients with microscopic extension of disease beyond the gland and a minimum 5-year followup. Of the patients 22 received adjuvant external beam radiation therapy and 23 did not. The groups were comparable with regard to significant prognostic variables. Patient selection was by surgeon preference. Local recurrences were seen in 1 of 22 patients (5 per cent) receiving adjuvant radiotherapy and 7 of 23 (30 per cent) undergoing an operation alone (p less than 0.05). Of 8 patients with local recurrence 7 died of the disease. Delayed radiotherapy of a local recurrence generally was not effective in controlling the disease. Of the 11 patients who died of prostatic cancer with a mean followup of 9.2 years 3 received adjuvant radiotherapy and 8 did not. Severe but nonfatal long-term complications were seen in 14 per cent of the irradiated patients and 6 per cent of those treated with an operation alone. Most of the complications occurred in the earlier years of the study in patients who received 60cobalt radiotherapy. When clinical stage B cancer of the prostate is found to be pathological stage C following radical perineal prostatectomy, adjuvant radiotherapy can decrease the incidence of subsequent local recurrence. The potential risk of adjuvant radiation therapy should be weighed and its use considered, particularly in patients whose tumor extends to the surgical margins or who have seminal vesicle invasion.

Carcinoma of the prostate: local control with external beam radiation therapy.

Local clinical control of the primary disease was evaluated in 209 patients with stage C adenocarcinoma of the prostate treated with definitive external beam radiation therapy and followed for a minimum of 2 years. Of these patients 92 per cent required no further prostatic operations for obstruction. Prostatectomy before therapy did not necessarily prevent later prostatic obstruction from occurring. Of 129 patients who had only a needle biopsy before irradiation 90 per cent had improvement of the obstructive and/or irritative symptoms as tumor regression occurred with therapy and these patients did not require a later prostatic operation for obstruction. Stricture formation occurred in 8 per cent of the patients and was not influenced by the type of preirradiation prostatic operation done. If transurethral resection was reuqired after irradiation it was technically more difficult but the morbidity was acceptable. The incidence of hematuria and incontinence was far less than that reported in non-irradiated patients with this disease. Most tumors exhibited a down-grading effect after irradiation. There were no deaths attributable to the treatment. Over-all, 83 per cent of the 209 patients had no urinary complaints after completion of therapy. From a urological viewpoint, good clinical local control is achieved in the patient with stage C adenocarcinoma of the prostate treated with external beam radiation therapy.

A frameless method for stereotactic radiotherapy

A frameless method for stereotactic multiple arc radiotherapy (SMART) is described. Three short gold wires are implanted in the scalp approximately 100 mm apart. These are localized in a computed tomographic or angiographic study along with the target. Subsequently the gold markers are localized on beam films and the target position calculated using a computer program ISOLOC. This program provides the couch movements required to move the target to the isocentre and a micropositioner attached to the couch is used to make the adjustment. Beam films are repeated until the movements required are less than 1 mm in any direction. It is shown that the simple procedures of implanting the markers subcutaneously do not provide a stable reference system in about 25% of patients and the markers are now screwed into the cranium. The precision of the method is evaluated by phantom studies and measurements taken during several hundred treatments.

An estimate of the margin required when defining blocks around the prostate

The portal films of 54 consecutive patients treated for primary prostate cancer have been compared to the simulation films. The systematic and random uncertainty in the set-up, defined by the couch movement required to move the patient to the simulated position, was determined to be 1.6 mm UP (SD 3.3 mm), 0.3 mm RT (SD 2.6 mm) and 1.3 mm IN (SD 2.4 mm). The area of fields defined on simulation films was compared with that on portal films to determine the error in block production which was -0.7 mm (SD = 0.9 mm). Five sources of uncertainty in the radiotherapy have been identified, three occur before and two during the course of treatment. A method for combining these uncertainties is proposed and used on the data obtained in this study. This provides estimates of the margin required when drawing blocks so that the minimum dose to the target is 95% of the prescription in 95% of treatments. The block margins are not uniform and range from 21 mm, when drawing the block outline to the posterior on a lateral film, to 13 m when drawing laterally on an anterior film.

Are pelvic irradiation and routine staging laparotomy necessary in clinically staged IA and IIA Hodgkin's disease?

Thirty‐nine patients with clinically staged IA and IIA Hodgkins disease were treated with mantle plus paraaortic/splenic irradiation between 1968 and 1975. All patients had supradiaphragmatic presentations, and none had staging laparotomies. With a follow‐up time of 1 to 9 years, mean 4.3 years, the overall relapse‐free survival is 92% (100% for stage IA and 89% for stage IIA). The absolute relapse‐free 5‐year survival is 91% There were no pelvic recurrences. These data show that routine staging laparotomy and pelvic irradiation are not indicated for clinically staged IA and IIA Hodgkins disease with supradiaphragmatic presentations. The criteria for staging laparotomy in early‐stage Hodgkins disease are discussed. Cancer 40:2914‐2916, 1977.

Combination transurethral resection, systemic chemotherapy, and pelvic radiotherapy for invasive (T2–T4) bladder cancer unsuitable for cystectomy: a phase I/II southwestern oncology group study

OBJECTIVES Primarily to evaluate the toxicity and, secondarily, the tumor response and patient survival associated with a three-phase combined modality treatment plan for patients with invasive transitional cell carcinoma (TCC) of the bladder (T2-T4,NX-N2, MO) who are medically unsuitable for or who refuse cystectomy. METHODS Eligible patients initially underwent extensive transurethral resection (TUR) of the primary tumor with the attempt to resect disease totally. Subsequently, they received systemic combination chemotherapy consisting of two cycles of methotrexate, cisplatin, and vinblastine (MCV), followed by cystoscopic re-evaluation of the bladder tumor. Patients then received 6480 cGy radiotherapy to the bladder with concurrent systemic cisplatin. Toxicity, primary tumor response, and overall survival were evaluated. RESULTS Of 34 eligible patients, 27 patients completed the treatment series. Twenty-two received 80% to 100% of the prescribed doses of MCV and only 2 patients experienced grade 4 hematologic toxicities. The most common toxicities were gastrointestinal (23), hematologic (21), and renal (8). The complete response (CR) rate after all treatment phases was 56% (19 of 34), 10 patients achieving a complete tumor resection of visible tumor at the initial TUR of the bladder (TURB); 3, a CR after MCV; and 6, after radiotherapy and concomitant cisplatin. The median overall survival was 21 months with 6 of 34 (18%) alive at 57 months (range, 36 to 75). Complete resection of tumor by TURB was associated with prolonged overall survival. The bladder was the initial site of recurrence in 85% of patients who had achieved a CR status. CONCLUSIONS This older age patient group tolerated this combined modality therapy with acceptable toxicities, but the overall survival rate was not improved compared with those reported with radiotherapy alone.

Combined modality therapy for advanced, diffuse lymphocytic and histiocytic lymphomas

Forty‐six previously untreated patients with advanced aggressive non‐Hodgkins (34 poorly differentiated and mixed diffuse, 8 histiocytic and 4 undifferentiated) were treated with a 3 phase combined modality program employing cyclophosphamide (C), hydroxyl‐daunomycin (H), vincristine (O), prednisone (P), procarbazine (P) [CHOP(P)] combination chemotherapy in an initial induction phase, radiotherapy and nonmarrow toxic chemotherapy as a second consolidation phase, followed by a third phase of CHOP(P) chemotherapy for four more cycles. Long‐term maintenance therapy was not given. High dose involved field radiation in phase II was limited to volumes encompasing less than 50% of the marrow bearing skeleton. The large majority of patients (82%) had such widespread involvement that this limitation precluded the use of local radiation and were treated instead with a mean of 132 rad of fractionated total body irradiation (TBI). Thirty‐eight patients (83%) achieved complete remission. Twenty‐nine (66%) of the 44 patients evaluable for follow‐up, and 22 (61%) of the 36 patients receiving TBI, remain alive in complete remission for observation periods of up to 26 months. Cancer 42:1697–1704, 1978.

A method for the assessment of the output of irregularly shaped electron fields

A simple approach to the calculation of dose in cone-collimated electron fields is presented. The method accounts for variations in lateral scatter with field size using a Clarkson Integration. The reduction in output by an irregularly shaped aperture is evaluated based on measurements of the output at various distances from the aperture in a field 2.5 cm in diameter. The first 14 months of clinical use were analysed and it is shown that in 42 out of 600 calculations, the cutout factor was less than 0.95 and that in 77% of these, the calculation method was accurate to +/- 3%.

Radiotherapy treatment planning using lymphoscintigraphy

A method for the three dimensional location of lymph nodes with respect to the skin surface is described. The technique is based on the reconstruction of surface shape using isocentric radiographs taken with metal chains draped on the patient. Registration of the radiographic study to the lymphoscintigraphic study is accomplished automatically by matching the location of four radiopaque and radioisotope markers. This method allows nodes to be located in a beams eye view with any set up of an isocentric radiotherapy machine. An accurate determination of the depth of lymph nodes is obtained, which is of value in electron beam therapy.

A radiolucent bite-block apparatus

A bite-block, patient immobilization apparatus has been constructed using all plastic parts. The apparatus may be used in C-T scanning without detriment to the images produced. The construction details are given and the procedure used to produce a bite block is described. A method to reduce electron backscattering onto the buccal mucosa from metal fillings is given.